Navigation Links
Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
Date:2/1/2010

RICHMOND, Calif., Feb. 1 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(TM) development programs and an overview of the company's business strategy at 9:00 am ET on Monday, February 8, 2010 at the 12th Annual BIO CEO & Investor Conference which will be held in New York City.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification.  The most advanced ZFP Therapeutic(TM) development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS and another Phase 1 trial to evaluate safety and clinical effect of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's web site at http://www.sangamo.com/.

SOURCE Sangamo BioSciences, Inc.

RELATED LINKS
http://www.sangamo.com

'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
2. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
3. Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast
4. Sangamo Announces Pricing of Public Offering of Common Stock
5. Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement
6. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
7. Sangamos Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells
8. Sangamo BioSciences Reports Second Quarter 2009 Financial Results
9. Sangamo BioSciences Announces Second Quarter 2009 Conference Call and Webcast
10. Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference
11. Sangamo BioSciences Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... (PRWEB) , ... April 27, 2016 , ... ... Lamka, PhD to its Scientific Advisory Board. Dr. Lamka will assist PathSensors in ... pathogen detection. , PathSensors deploys the CANARY® test platform for the detection ...
(Date:4/27/2016)... 27, 2016 MedDay, a biotechnology company ... the appointment of Catherine Moukheibir as Chairman of its Board ... Jean Jacques Garaud , who contributed to the rapid ... immediately. Catherine started her career in strategy consulting ... London .  She held C-Suite level roles ...
(Date:4/26/2016)... ... April 26, 2016 , ... The European Patent Office ... as one of three finalists for the European Inventor Award 2016 in the category ... will be announced at a ceremony in Lisbon on June 9th. , The human ...
(Date:4/26/2016)... MD (PRWEB) , ... April 26, 2016 , ... ... a $1.8M Series A round of financing. Healthy investor interest drove significant oversubscription ... portfolio of generic biologics, known as biosimilars, to the advanced preclinical stages. , Chief ...
Breaking Biology Technology:
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting Medicaid ... setting a new clinical standard in telehealth thanks to ... leveraging the higi platform, IMPOWER patients can routinely track ... and body mass index, and, when they opt in, ... convenient visit to a local retail location at no ...
(Date:3/22/2016)... March 22, 2016 ... Sensors Market for Consumer Industry by Type (Image, ... Application (Communication & IT, Entertainment, Home Appliances, ... Forecast to 2022", published by MarketsandMarkets, the ... to reach USD 26.76 Billion by 2022, ...
(Date:3/15/2016)... , March 15, 2016 ... report published by Transparency Market Research "Digital Door Lock Systems ... Forecast 2015 - 2023," the global digital door lock systems ... Mn in 2014 and is forecast to grow at a ... of micro, small and medium enterprises (MSMEs) across the world ...
Breaking Biology News(10 mins):